CLEVELAND, December 19, 2019 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) today announced that Sparrow Health System in Lansing, Mich. began patient treatments with MRIdian® Linac, a state-of-the-art radiation therapy system that combines the latest innovations in precision radiation delivery and revolutionary MRI guidance. The MRIdian device is located in the hospital’s new Herbert-Herman Cancer Center, designed to provide convenient and comprehensive patient care.
During the first weeks of treating patients with MRI scans, the Sparrow Health System team was able to treat difficult cases such as pancreatic cancer and central lung injury. MRIdian’s precision allows the team to deliver Stereotactic Body Radiation Therapy (SBRT) – high doses of radiation delivered to targeted areas. The goal of SBRT is to irradiate the tumor, lessen the side effects and impact on surrounding healthy tissue, and provide greater patient convenience as fewer treatment sessions are required.
“This is breakthrough technology. We are able to capture high resolution images while simultaneously delivering radiation therapy. This increases the treatment options available to our cancer patients,” said Luciano DiCarlo, MD, radiation oncologist, Sparrow Herbert-Herman Cancer Center. “With MRIdian, we can now see what’s going on inside the body as we deliver treatment to ensure we’re targeting the cancer and avoiding nearby healthy tissues and organs. This takes radiation therapy to a whole new level. level and allows us to deliver higher doses. We are bringing a more precise and personalized approach to radiotherapy.”
Unlike conventional radiation therapy, the MRIdian system provides diagnostic-grade MRI visualization of target soft tissues and surrounding organs. With MRIdian, clinicians can make daily modifications to the tabletop treatment plan to dynamically adjust radiation beam delivery to subtle anatomical changes that may occur, both during treatment delivery and throughout treatment. Combined, these capabilities offer the possibility of improving targeting accuracy and therefore delivering higher radiation doses.
“Advancing MRIdian’s innovation beyond academic institutions is an important step in patient care, as the vast majority of cancer patients in the United States receive treatment in a community hospital setting,” said Jim Alecxih, commercial director of ViewRay. “Sparrow Health System has used adaptive tabletop therapy in complex cases from day one of treatment, leveraging the breadth of MRIdian’s specialized capabilities. This is a significant advance in cancer care for patients around the world.
ViewRay’s MRIdian system has already been installed in 31 leading hospitals around the world where it is used to treat a wide variety of solid tumors and is the subject of numerous ongoing clinical trials. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. Over 6,500 patients have been treated with MRIdian. For a list of treatment centers, please visit: https://viewray.com/mridian-locator.
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® Radiation Therapy System. MRIdian is built on a proprietary high-definition MR imaging system designed from the ground up to meet the unique challenges and clinical workflow of advanced radiation oncology. Unlike MRI systems used in diagnostic radiology, MRIdian’s high-definition MRI has been specifically designed to address specific challenges including beam distortion, skin toxicity, and other issues that can arise when high magnetic fields interact with beams of radiation. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, among other things, the rate of new orders, upgrades and installations, ViewRay’s financial guidance for the full year 2019 and ViewRay’s conference call to discuss its second trimester. Actual results could differ from those projected in the forward-looking statements due to many factors. These factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay’s products, ability to convert backlog into revenue and timing of delivery of ViewRay’s products, timing, results and other uncertainties associated with clinical trials, the ability to raise additional funds necessary to continue to pursue ViewRay’s business and product development plans, inherent uncertainties associated with the development of new products or technologies, competition in the industry in which ViewRay operates and general market conditions. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay’s business generally, see ViewRay’s current and future reports filed with of the Securities and Exchange Commission, including its annual report on Form 10-K for the fiscal year ended December 31, 2018 and its quarterly reports on Form 10-Q for the quarters March 31, 2019, June 30, 2019and September 30, 2019 as updated from time to time by the Company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay undertakes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. , except as required by law.
SOURCE ViewRay, Inc.